Clinical Trial Update: Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating elacestrant versus standard of care for ER+/HER2- advanced breast cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Elacestrant (elacestrant)

Snippet

Sponsor: Stemline Therapeutics, Inc. | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-12-05